# Genetic Predictors of Benefit to Pembrolizumab

> **NCT02710396** · PHASE2 · TERMINATED · sponsor: **Columbia University** · enrollment: 19 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Carboplatin
- **DRUG:** Nab-paclitaxel
- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT02710396
- **Lead sponsor:** Columbia University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-05-31
- **Primary completion:** 2021-03-10
- **Final completion:** 2021-03-10
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** Frontline pembrolizumab approved in NSCLC as monotherapy and in combination with chemotherapy representing a new standard of care.
- **Last updated:** 2023-07-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02710396

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02710396, "Genetic Predictors of Benefit to Pembrolizumab". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02710396. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*